Clinical Trials Browser

Recurrence × enzalutamide × 30 days × Clear all

NCT03460977 2026-05-20

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Phase 1 Recruiting

LymphoidThoracic

Lymphoma, Follicular, Recurrence, Small Cell Lung Carcinoma

NCT06551324 2026-05-05

MEVPRO-1

Phase 3 Active not recruiting

Prostatic Neoplasms, Recurrence